Recent Updates
Recently added Catalysts
BMRN Positive Sentiment Score: 75/100

BioMarin to Present at the BofA Securities 2024 Health Care Conference on Wednesday, May 15 at 10:00am PT / 1:00pm ET, in Las Vegas, NV BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President, and Chief Executive Officer of BioMarin will present at...

Key Takeaway: BioMarin Pharmaceutical Inc. has announced that its CEO, Alexander Hardy, will be presenting at the BofA Securities 2024 Healthcare Conference on May 15, 2024. The presentation will be accessible via live audio webcast, with an archived version available later on the company's website. BioMarin is known for its focus on genetic discovery and has developed eight commercial therapies targeting rare genetic disorders.

Market Sentiment Analysis

POSITIVE FACTORS

  • BioMarin is actively engaging with investors through presentations.
  • The upcoming conference showcases BioMarin's innovations in genetic therapies.
  • BioMarin has a history of developing successful treatments for rare genetic disorders.

Full Press Release Details

SAN RAFAEL, Calif. , May 8, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) today announced that Alexander Hardy , President, and Chief Executive Officer of BioMarin will present at the BofA Securities 2024 Healthcare Conference on Wednesday, May 15, 2024 , at 10:00am PT / 1:00pm ET , in Las Vegas, Nevada .
An audio webcast of the presentation will be available live. You can access the webcast at: https://investors.biomarin.com/ . An archived version of the remarks will also be available through the Company's website for a limited time following the conference.
About BioMarin Founded in 1997, BioMarin is a global biotechnology Company dedicated to transforming lives through genetic discovery. The Company develops and commercializes targeted therapies that address the root cause of the genetic conditions. BioMarin's unparalleled research and development capabilities have resulted in eight transformational commercial therapies for patients with rare genetic disorders. The Company's distinctive approach to drug discovery has produced a diverse pipeline of commercial, clinical, and pre-clinical candidates that address a significant unmet medical need, have well-understood biology, and provide an opportunity to be first-to-market or offer a substantial benefit over existing treatment options. For additional information, please visit www.biomarin.com .
Contacts:
Investors Media
Traci McCarty Marni Kottle
BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc.
(415) 455-7558 (650) 374-2803
SOURCE BioMarin Pharmaceutical Inc.

21 %

Frequently Asked Questions

When will BioMarin's CEO present at the Healthcare Conference?

Alexander Hardy will present on May 15, 2024, at 10:00 am PT.

Where can I access the conference presentation webcast?

The webcast can be accessed at https://investors.biomarin.com/.

What does BioMarin specialize in?

BioMarin specializes in developing therapies for rare genetic disorders.

When was BioMarin founded?

BioMarin was founded in 1997.

How many therapies does BioMarin have on the market?

BioMarin has eight commercial therapies for rare genetic disorders.

Last updated: May 8, 2024